Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease the Women's Health Initiative Observational Study

Circulation: Cardiovascular Quality and Outcomes

Volumn 2, Issue 2, 2009, Pages 78-87

  Berger, Jeffrey S ^a,j   Brown, David L ^a,c   Burke, Gregory L ^b,d   Oberman, Albert ^e   Kostis, John B ^f   Langer, Robert D ^g   Wong, Nathan D ^h   Wassertheil Smoller, Sylvia ⁱ  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e University of Alabama at Birmingham   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^j Jackson Hole Center for Preventive Medicine   (United States)

more..

Author keywords

Aspirin; Cardiovascular disease; Dose; Drugs; Mortality; Observational Study; Women

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; DRUG USE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION; STROKE; TREATMENT OUTCOME; ANGINA PECTORIS; DOSE RESPONSE; FOLLOW UP; HEART INFARCTION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; SUDDEN DEATH; WOMEN'S HEALTH;

AGED; ANGINA PECTORIS; ASPIRIN; CARDIOVASCULAR DISEASES; DEATH, SUDDEN, CARDIAC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; STROKE; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 77949535656     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.108.791269     Document Type: Article

References (44)

1. Anonymous. Collaborative overview of randomised trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' collaboration. BMJ. 1994; 308: 81-106.
2. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86.
3. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE II, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Academic Emergency Medicine. American College of Cardiology/American Heart Association 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American heart association task force on practice guidelines (Writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction) : developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007; 116: e148-e304.
4. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC, National Heart LABI. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113: 2363-2372. (Pubitemid 43947981)
5. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med. 2008;121:43-49.
6. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007; 297: 2018-2024. (Pubitemid 46740354)
7. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004; 126: 234S-264S.
8. Kong DF, Hasselblad V, Kandzari DE, Newby LK, Califf RM. Seeking the optimal aspirin dose in acute coronary syndromes. Am J Cardiol. 2002; 90: 622-625.
9. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, Ganiats TG, Gomes AS, Gornik HL, Gracia C, Gulati M, Haan CK, Judelson DR, Keenan N, Kelepouris E, Michos ED, Newby LK, Oparil S, Ouyang P, Oz MC, Petitti D, Pinn VW, Redberg RF, Scott R, Sherif K, Smith SC Jr, Sopko G, Steinhorn RH, Stone NJ, Taubert KA, Todd BA, Urbina E, Wenger NK; Expert Panel/Writing Group, American Heart Association, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, American College of Cardiology Foundation, Society of Thoracic Surgeons, American Medical Women's Association, Centers for Disease Control and Prevention, Office of Research on Women's Health, Association of Black Cardiologists, American College of Physicians, World Heart Federation, National Heart Lung and Blood Institute, American College of Nurse Practitioners. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007; 115: 1481-1501.
10. Anonymous. Design of the women's health initiative clinical trial and observational study. The women's health initiative study group. Controlled Clinical Trials. 1998; 19: 61-109.
11. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The women's health initiative observational study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol. 2003; 13: S107-S121.
12. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist Medicine. 1998; 17: 2265-2281.
13. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am Journal Epidemiol. 1999; 150: 327-333.
14. Becker RC, Terrin M, Ross R, Knatterud GL, Desvigne-Nickens P, Gore JM, Braunwald E. Comparison of clinical outcomes for women and men after acute myocardial infarction. The thrombolysis in myocardial infarction investigators [see comment]. Ann Intern Med. 1994;120:638-645.
15. Califf RM, DeLong ER, Ostbye T, Muhlbaier LH, Chen A, LaPointe NA, Hammill BG, McCants CB, Kramer JM. Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol. 2002; 89: 653-661. (Pubitemid 34230559)
16. Chandra NC, Ziegelstein RC, Rogers WJ, Tiefenbrunn AJ, Gore JM, French WJ, Rubison M. Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I [see omment]. Arch Intern Med. 1998; 158: 981-988.
17. Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, Granger CB, Erickson S, White K, Steg PG. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004; 117: 73-81.
18. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, Wang Y, Jencks SF. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med. 1996; 124: 292-298.
19. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, Wang Y, Kresowik TF, Jencks SF. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. Circulation. 1995; 92: 2841-2847.
20. McLaughlin TJ, Soumerai SB, Willison DJ, Gurwitz JH, Borbas C, Guadagnoli E, McLaughlin B, Morris N, Cheng SC, Hauptman PJ, Antman E, Casey L, Asinger R, Gobel F. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med. 1996; 156: 799-805.
21. Shahar E, Folsom AR, Romm FJ, Bisgard KM, Metcalf PA, Crum L, McGovern PG, Hutchinson RG, Heiss G. Patterns of aspirin use in middle-aged adults: the atherosclerosis risk in communities (ARIC) study. Am Heart J. 1996; 131: 915-922.
22. Stafford RS. Aspirin use is low among United States outpatients with coronary artery disease. Circulation. 2000; 101: 1097-1101.
23. Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol. 2003; 55: 604-608.
24. Winkleby MA, Jatulis DE, Frank E, Fortmann SP. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease [see comment]. Am J Public Health. 1992; 82: 816-820.
25. Manor O, Eisenbach Z, Friedlander Y, Kark JD. Educational differentials in mortality from cardiovascular disease among men and women: the Israel Longitudinal Mortality Study. Ann Epidemiol. 2004; 14: 453-460.
26. Alter DA, Iron K, Austin PC, Naylor CD, Group SS. Socioeconomic status, service patterns, and perceptions of care among survivors of acute myocardial infarction in Canada. JAMA. 2004; 291: 1100-1107.
27. Groeneveld PW, Heidenreich PA, Garber AM. Racial disparity in cardiac procedures and mortality among long-term survivors of cardiac arrest. Circulation. 2003; 108: 286-291.
28. Eidelman RS, Lamas GA, Hennekens CH, Ridker PM. Aspirin, postmenopausal hormones, and C-reactive protein. Arch Intern Med. 2002;162:480-481.
29. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative I. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003; 349: 523-534.
30. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352: 1293-1304.
31. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006; 295: 306-313.
32. Escolar G, Bastida E, Garrido M, Rodriguez-Gomez J, Castillo R, Ordinas A. Sex-related differences in the effects of aspirin on the interaction of platelets with subendothelium. Thrombosis Res. 1986; 44: 837-847.
33. Spranger M, Aspey BS, Harrison MJ. Sex difference in antithrombotic effect of aspirin. Stroke. 1989; 20: 34-37.
34. Anonymous. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 1980; 243: 661-669.
35. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet. 1979; 2: 1313-1315.
36. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis [see comment]. JAMA. 2001; 286: 1187-1194.
37. Harpaz D, Benderly M, Goldbourt U, Kishon Y, Behar S. Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia. Israeli BIP Study Group. Am J Cardiol. 1996; 78: 1215-1219.
38. Higashi T, Shekelle PG, Solomon DH, Knight EL, Roth C, Chang JT, Kamberg CJ, MacLean CH, Young RT, Adams J, Reuben DB, Avorn J, Wenger NS. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med. 2004; 140: 714-720.
39. Anonymous. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med. 1991; 325: 1261-1266.
40. Berger JS, Stebbins A, Granger CB, Ohman EM, Armstrong PW, Van de Werf F, White HD, Simes RJ, Harrington RA, Califf RM, Peterson ED. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation. 2008; 117: 192-199.
41. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S. Clopidogrel in Unstable angina to prevent Recurrent Events Trial I. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Circulation. 2003; 108: 1682-1687.
42. Quinn MJ, Aronow HD, Califf RM, Bhatt DL, Sapp S, Kleiman NS, Harrington RA, Kong DF, Kandzari DE, Topol EJ. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am College Cardiol. 2004; 43: 972-978.
43. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, Simard D, Silver FL, Hachinski V, Clagett GP, Barnes R, Spence JD. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet. 1999;353:2179-2184.
44. Radford MJ, Foody JM. How do observational studies expand the evidence base for therapy? JAMA. 2001; 286: 1228-1230.